Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 425

1.

Engineering Approaches to Study Cellular Decision-Making.

Kreeger PK, Strong LE, Masters KS.

Annu Rev Biomed Eng. 2018 Jan 12. doi: 10.1146/annurev-bioeng-062117-121011. [Epub ahead of print]

PMID:
29328778
2.

Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report.

Goldsby RE, Stratton KL, Raber S, Ablin A, Strong LC, Oeffinger K, Sklar CA, Armstrong GT, Robison LL, Bhatia S, Leisenring WM.

Cancer. 2018 Feb 1;124(3):617-625. doi: 10.1002/cncr.31065. Epub 2017 Nov 3.

PMID:
29105081
3.

Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.

Morton LM, Sampson JN, Armstrong GT, Chen TH, Hudson MM, Karlins E, Dagnall CL, Li SA, Wilson CL, Srivastava DK, Liu W, Kang G, Oeffinger KC, Henderson TO, Moskowitz CS, Gibson TM, Merino DM, Wong JR, Hammond S, Neglia JP, Turcotte LM, Miller J, Bowen L, Wheeler WA, Leisenring WM, Whitton JA, Burdette L, Chung C, Hicks BD, Jones K, Machiela MJ, Vogt A, Wang Z, Yeager M, Neale G, Lear M, Strong LC, Yasui Y, Stovall M, Weathers RE, Smith SA, Howell R, Davies SM, Radloff GA, Onel K, Berrington de González A, Inskip PD, Rajaraman P, Fraumeni JF Jr, Bhatia S, Chanock SJ, Tucker MA, Robison LL.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx058.

PMID:
29059430
4.

Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.

Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC.

Fam Cancer. 2018 Apr;17(2):287-294. doi: 10.1007/s10689-017-0034-6.

PMID:
28988289
5.

Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Zhou R, Xu A, Gingold J, Strong LC, Zhao R, Lee DF.

Trends Pharmacol Sci. 2017 Oct;38(10):908-927. doi: 10.1016/j.tips.2017.07.004. Epub 2017 Aug 14. Review.

PMID:
28818333
6.

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.

Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak R, Balieiro da Costa A, Santiago KM, Garber J, O'Neill AF, Eeles RA, Evans DG, Bleiker E, Sonke GS, Ruijs M, Loo C, Schiffman J, Naumer A, Kohlmann W, Strong LC, Bojadzieva J, Malkin D, Rednam SP, Stoffel EM, Koeppe E, Weitzel JN, Slavin TP, Nehoray B, Robson M, Walsh M, Manelli L, Villani A, Thomas DM, Savage SA.

JAMA Oncol. 2017 Dec 1;3(12):1634-1639. doi: 10.1001/jamaoncol.2017.1968.

PMID:
28772291
7.

A Retrospective on the Vision for Progress in Community Health Partnerships: Research, Education, and Action.

Eder MM, Holzer J, Calhoun K, Strong LL.

Prog Community Health Partnersh. 2017;11(1):1-11. doi: 10.1353/cpr.2017.0001.

8.

Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.

Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer MC, Hansford JR, Janeway KA, Kohlmann WK, McGee R, Mullighan CG, Onel K, Pajtler KW, Pfister SM, Savage SA, Schiffman JD, Schneider KA, Strong LC, Evans DGR, Wasserman JD, Villani A, Malkin D.

Clin Cancer Res. 2017 Jun 1;23(11):e38-e45. doi: 10.1158/1078-0432.CCR-17-0408. Review.

PMID:
28572266
9.

Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions.

Porter CC, Druley TE, Erez A, Kuiper RP, Onel K, Schiffman JD, Wolfe Schneider K, Scollon SR, Scott HS, Strong LC, Walsh MF, Nichols KE.

Clin Cancer Res. 2017 Jun 1;23(11):e14-e22. doi: 10.1158/1078-0432.CCR-17-0428. Review.

PMID:
28572263
10.

The psychosocial effects of the Li-Fraumeni Education and Early Detection (LEAD) program on individuals with Li-Fraumeni syndrome.

Ross J, Bojadzieva J, Peterson S, Noblin SJ, Yzquierdo R, Askins M, Strong L.

Genet Med. 2017 Sep;19(9):1064-1070. doi: 10.1038/gim.2017.8. Epub 2017 Mar 16.

11.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

12.

Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.

Peng G, Bojadzieva J, Ballinger ML, Li J, Blackford AL, Mai PL, Savage SA, Thomas DM, Strong LC, Wang W.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):837-844. doi: 10.1158/1055-9965.EPI-16-0695. Epub 2017 Jan 30.

PMID:
28137790
13.

Community Perceptions of Biobanking Participation: A Qualitative Study among Mexican-Americans in Three Texas Cities.

Heredia NI, Krasny S, Strong LL, Von Hatten L, Nguyen L, Reininger BM, McNeill LH, Fernández ME.

Public Health Genomics. 2017;20(1):46-57. doi: 10.1159/000452093. Epub 2016 Dec 8.

14.

An evidence-based conceptual framework of healthy cooking.

Raber M, Chandra J, Upadhyaya M, Schick V, Strong LL, Durand C, Sharma S.

Prev Med Rep. 2016 May 17;4:23-8. doi: 10.1016/j.pmedr.2016.05.004. eCollection 2016 Dec.

15.

Perspectives of Mexican-origin smokers on healthy eating and physical activity.

Strong LL, Hoover DS, Heredia NI, Krasny S, Spears CA, Correa-Fernández V, Wetter DW, Fernandez ME.

Health Educ Res. 2016 Aug;31(4):465-77. doi: 10.1093/her/cyw026. Epub 2016 May 30.

16.

CANCER. The cancer predisposition revolution.

Malkin D, Garber JE, Strong LC, Friend SH.

Science. 2016 May 27;352(6289):1052-3. doi: 10.1126/science.aag0832. No abstract available.

PMID:
27230363
17.

Measuring Nurse Caring Behaviors in the Hospitalized Older Adult.

Goncalves SA, Strong LL, Nelson M.

J Nurs Adm. 2016 Mar;46(3):132-8. doi: 10.1097/NNA.0000000000000312.

PMID:
26866325
18.

Enzyme- and pH-Responsive Microencapsulated Nanogels for Oral Delivery of siRNA to Induce TNF-α Knockdown in the Intestine.

Knipe JM, Strong LE, Peppas NA.

Biomacromolecules. 2016 Mar 14;17(3):788-97. doi: 10.1021/acs.biomac.5b01518. Epub 2016 Feb 11.

PMID:
26813877
19.

Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.

Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K.

Ann Oncol. 2016 May;27(5):795-800. doi: 10.1093/annonc/mdw018. Epub 2016 Jan 19.

20.

Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study.

Henderson TO, Moskowitz CS, Chou JF, Bradbury AR, Neglia JP, Dang CT, Onel K, Novetsky Friedman D, Bhatia S, Strong LC, Stovall M, Kenney LB, Barnea D, Lorenzi E, Hammond S, Leisenring WM, Robison LL, Armstrong GT, Diller LR, Oeffinger KC.

J Clin Oncol. 2016 Mar 20;34(9):910-8. doi: 10.1200/JCO.2015.62.3314. Epub 2015 Dec 23.

Supplemental Content

Loading ...
Support Center